Lu Anti-Pharma plans to invest 45.6 million yuan to set up a biomanufacturing company

Lu Anti-Pharma intends to invest 45.6 million yuan to set up Lu Anti-Biomanufacturing Company, the company registered capital of 48 million yuan, the company's shareholding of 95%In addition, the Company intends to sell its 31.25% stake in Meiji Lu anti-Japanese company to Japan's Meiji Fruit Co., Ltdat a price of no less than $1.115 per share of net assetsLu Anti-Pharmaceutical (600789) issued a notice on March 27, said that in order to further strengthen the large company's biopharmaceutical products, give full play to the company's fermentation industrialization advantages, to achieve the continued, leapfrog development of Lu anti-resistance, the company intends to set up a holding subsidiary Shandong Lu anti-biomanufacturing Co., Ltdthe company's registered capital of 48 million yuan, of which the company's initial capital contribution of 45.6 million yuan, accounting for 95% of the investment ratio, Shandong Lu anti-Sherile Pharmaceutical Co., Ltdinvestment amount of 2.4 million yuan, accounting for 5% of the investment ratioIts business scope for chemical raw materials and preparations, biological materials, amino acids, pharmaceutical production of chemical raw materials, accessories and intermediates, veterinary drugs, starch sugar, such as manufacturing, processing, sales;in addition, after friendly negotiations between the company and Meiji Lu Anti-Pharmaceutical Co., Ltd., the largest shareholder of Meiji Lu Pharmaceutical Co., Ltd., the Company intends to sell its 31.25% stake in Meiji Lu Anti-Pharmaceutical Co., Ltdat a price of not less than 1.115 yuan per share of net assets, and sell it all at a time to Meiji Fruit Co., Ltdof JapanAfter the shareholders of both parties have engaged intermediary institutions for audit and evaluation, the transfer of listingshalled persons shall be handled in accordance with the relevant procedures of the SASAC of Shandong Province on the transfer of property rightsMeiji Lu Anti is a Sino-foreign joint venture jointly funded by the company and Japan Meiji Fruit Co., Ltdand Japan's Alista Life Sciences Co., Ltdin October 2003 in Jining City, Shandong Province, jointly funded by the high-tech development zone, mainly engaged in the production of meditymycin, sulfuric acid adhesive rod productsThe Company invested US$7.5 million, or 31.25 per cent of the total share capital, us$12.5 million, or 52.08 per cent of the total share capital, and US$4 million, or 16.67 per cent of the total share capital, by Meiji Fruit Co., LtdLu Anti-Pharma intends to invest 45.6 million yuan to set up Lu Anti-Biomanufacturing Company, the company registered capital of 48 million yuan, the company's shareholding of 95%In addition, the Company intends to sell its 31.25% stake in Meiji Lu anti-Japanese company to Japan's Meiji Fruit Co., Ltd at a price of no less than $1.115 per share of net assets Lu Anti-Pharmaceutical (600789) issued a notice on March 27, said that in order to further strengthen the large company's biopharmaceutical products, give full play to the company's fermentation industrialization advantages, to achieve the continued, leapfrog development of Lu anti-resistance, the company intends to set up a holding subsidiary Shandong Lu anti-biomanufacturing Co., Ltd the company's registered capital of 48 million yuan, of which the company's initial capital contribution of 45.6 million yuan, accounting for 95% of the investment ratio, Shandong Lu anti-Sherile Pharmaceutical Co., Ltd investment amount of 2.4 million yuan, accounting for 5% of the investment ratio Its business scope for chemical raw materials and preparations, biological materials, amino acids, pharmaceutical production of chemical raw materials, accessories and intermediates, veterinary drugs, starch sugar, such as manufacturing, processing, sales; in addition, after friendly negotiations between the company and Meiji Lu Anti-Pharmaceutical Co., Ltd., the largest shareholder of Meiji Lu Pharmaceutical Co., Ltd., the Company intends to sell its 31.25% stake in Meiji Lu Anti-Pharmaceutical Co., Ltd at a price of not less than 1.115 yuan per share of net assets, and sell it all at a time to Meiji Fruit Co., Ltd of Japan After the shareholders of both parties have engaged intermediary institutions for audit and evaluation, the transfer of listingshalled persons shall be handled in accordance with the relevant procedures of the SASAC of Shandong Province on the transfer of property rights Meiji Lu Anti is a Sino-foreign joint venture jointly funded by the company and Japan Meiji Fruit Co., Ltd and Japan's Alista Life Sciences Co., Ltd in October 2003 in Jining City, Shandong Province, jointly funded by the high-tech development zone, mainly engaged in the production of meditymycin, sulfuric acid adhesive rod products The Company invested US$7.5 million, or 31.25 per cent of the total share capital, us$12.5 million, or 52.08 per cent of the total share capital, and US$4 million, or 16.67 per cent of the total share capital, by Meiji Fruit Co., Ltd (name)